

Journal of Visualized Experiments

Inactivation of mTor: A tool to investigate meiotic progression and translational control during bovine oocyte maturation --Manuscript Draft--

Manuscript Number:	JoVE53689R3
Full Title:	Inactivation of mTor: A tool to investigate meiotic progression and translational control during bovine oocyte maturation
Article Type:	Invited Methods Article - JoVE Produced Video
Keywords:	Bovine oocyte, in vitro maturation, meiotic maturation, mTor, inhibitors, translational control, 4E-BP1
Manuscript Classifications:	95.51.3: animal biology; 95.51.6: biochemistry
Corresponding Author:	Ralf Pöhland Leibniz Institute for Farm Animal Biology Dummerstorf, Germany GERMANY
Corresponding Author Secondary Information:	
Corresponding Author E-Mail:	poehland@fhn-dummerstorf.de
Corresponding Author's Institution:	Leibniz Institute for Farm Animal Biology
Corresponding Author's Secondary Institution:	
First Author:	Manuela Kreißelmeier
First Author Secondary Information:	
Other Authors:	Manuela Kreißelmeier
	Sophia Mayer
	Christine Wrenzycki
	Ralf Pöhland
Order of Authors Secondary Information:	
Abstract:	Although routinely used in breeding programs, in vitro maturation (IVM) of bovine oocytes and in vitro production (IVP) of embryos are nevertheless still the subject of basic research owing to suboptimal IVM conditions and variations in the developmental competence of the starting oocytes. In the present study we provide a method to inhibit the Ser/Thr kinase mTor during IVM using two independent inhibitors, Torin2 and Rapamycin. Both substances have different effects on meiotic progression and translational control and may allow discrimination between the mTorC1 and mTorC2 complex functions. The effects of the inhibitors are monitored by inspection of the chromatin configuration using aceto-orcein-staining as well as Western blotting and immunohistochemical analysis of the phosphorylation state of the translational repressor 4E-BP1, which is a prominent mTor target. Whereas Torin2 arrests bovine oocytes in the M I stage and inhibits 4E-BP1 phosphorylation, Rapamycin inhibits asymmetric division and does not influence 4E-BP1. Investigations utilizing these reactions can provide deeper insights into the regulatory events involved in meiotic maturation. Moreover, special focus can be placed on the temporal and spatial regulation of translational control. Such findings can contribute to the definition of the developmental competence of oocytes and to an improvement of IVM conditions.
Author Comments:	I am Ralf Pöhland and acting in behalf of Wolfgang Tomek. Please contact me at poehland@fhn-dummerstorf.de
Additional Information:	
Question	Response

If this article needs to be filmed by a certain date to due to author/equipment/lab availability, please indicate the date below and explain in your cover letter.	
If this article needs to be "in-press" by a certain date to satisfy grant requirements, please indicate the date below and explain in your cover letter.	

Dear Editor-in-Chief,

I am writing on the behalf of publishing the article “Inactivation of mTor: A tool to investigate meiotic progression and translational control during bovine oocyte maturation” in JoVE. We think that the detailed presentation of the method of mammalian oocyte maturation and application of specific inhibitors may contribute, with regard to practical aspects as well as basic research, to achieve deeper insight in the complex regulation of oocyte maturation and meiotic progression.

This is an invited manuscript and was assisted by Mary Struziak.

Author contributions:

Manuela Kreißelmeier, Sophia Mayer performed IVM of oocytes and participated in all other approaches.

Christine Wrenzycki participated in the evaluation and interpretation of the data.

Ralf Pöhland conducted LSM

Wolfgang Tomek planed the project, designed the experiments, evaluated the data and drafted the manuscript.

As reviewers, we would recommend:

Dr. David Tesfaye; Email: tesfaye@itw.uni-bonn.de Animal Breeding and Husbandry Group, Department of Animal Breeding and Husbandry, Institute of Animal Science, University of Bonn, Endenicher allee 15, 53115 Bonn, Germany

Prof. Dr. Dr. R. Einspanier, einspani@zedat.fu-berlin.de, Freie Universität Berlin, Institute of Veterinary Biochemistry, Oertzenweg 19b, 14163 Berlin, Germany

Dr. M. Kubelka, kubelka@iapg.cas.cz, Institute for Animal physiology and genetics, Libechov, Czech Republik.

Sincerely,

Wolfgang Tomek

TITLE:

Inactivation of mTor: A tool to investigate meiotic progression and translational control during bovine oocyte maturation

AUTHORS:

Kreißelmeier, Manuela
BVN Neustadt/Aisch
Neustadt, Germany
manu-krm@gmx.de

Mayer, Sophia
BVN Neustadt/Aisch
Neustadt, Germany
Ostermeier.Sophia@gmx.net

Wrenzycki, Christine
Faculty of Veterinary Medicine, Clinic for Obstetrics, Gynecology and Andrology of Large and Small Animals,
Justus-Liebig-University Giessen
Giessen, Germany
Christine.Wrenzycki@vetmed.uni-giessen.de

Pöhland, Ralf
Reproductive Cell Biology Unit
Leibniz Institute for Farm Animal Biology
Dummerstorf, Germany
poehland@fhn-dummerstorf.de

Tomek, Wolfgang
Reproductive Biochemistry Unit
Leibniz Institute for Farm Animal Biology
Dummerstorf, Germany
tomek@fhn-dummerstorf.de

CORRESPONDING AUTHOR:

Pöhland, Ralf
Reproductive Cell Biology Unit
Leibniz Institute for Farm Animal Biology
Dummerstorf, Germany
tomek@fhn-dummerstorf.de

KEYWORDS:

Bovine oocyte, *in vitro* maturation, meiotic maturation, mTor, inhibitors, translational control, 4E-BP1

SHORT ABSTRACT:

The protocol presented here describes the inhibition of the Ser/Thr kinase mTor during IVM of bovine oocytes. This approach can facilitate the investigation of meiotic progression and translational control. It also contributes to the definition of developmental competence and the improvement of IVM conditions.

LONG ABSTRACT:

Although routinely used in breeding programs, *in vitro* maturation (IVM) of bovine oocytes and *in vitro* production (IVP) of embryos are nevertheless still the subject of basic research owing to suboptimal IVM conditions and variations in the developmental competence of the starting oocytes. In the present study we provide a method to inhibit the Ser/Thr kinase mTor during IVM using two independent inhibitors, Torin2 and Rapamycin. Both substances have different effects on meiotic progression and translational control and may allow discrimination between the mTorC1 and mTorC2 complex functions. The effects of the inhibitors are monitored by inspection of the chromatin configuration using aceto-orcein-staining as well as Western blotting and immunohistochemical analysis of the phosphorylation state of the translational repressor 4E-BP1, which is a prominent mTor target. Whereas Torin2 arrests bovine oocytes in the M I stage and inhibits 4E-BP1 phosphorylation, Rapamycin inhibits asymmetric division and does not influence 4E-BP1. Investigations utilizing these reactions can provide deeper insights into the regulatory events involved in meiotic maturation. Moreover, special focus can be placed on the temporal and spatial regulation of translational control. Such findings can contribute to the definition of the developmental competence of oocytes and to an improvement of IVM conditions.

INTRODUCTION:

Fully grown bovine oocytes (arrested at prophase I; germinal vesicle -GV- stage) resume meiosis spontaneously when they are released from their follicles and transferred to a suitable culture medium. Previous investigations using the application of different inhibitors to *in vitro* culture media^{1, 2} revealed that activation of protein kinases and *de novo* protein synthesis trigger the maturation of mammalian oocytes and arrest them in metaphase II (M II), the stage suitable for fertilization. In the present study we describe a method to inhibit the Ser/Thr kinase mTor during IVM of bovine oocytes. This approach might provide deeper insights into the complex processes involved in the regulation of protein synthesis in the context of meiotic maturation (transition from GV-stage to M II), because mTor links the phosphorylation of specific factors directly to translational control^{3, 4}.

The focus on the investigation of translational control reflects the importance of this process; fully grown oocytes are transcriptionally silent and protein synthesis relies on the activation of stored, dormant mRNAs⁵. In this context, mTor plays a predominant role. The kinase directly phosphorylates and inactivates repressors of the mRNA cap-binding protein eIF4E, the so-called 4E-binding proteins (4E-BP1-3), and thereby allows the formation of the 5'-mRNA-cap binding complex eIF4F (composed of eIF4E, the scaffold protein eIF4G and the RNA helicase eIF4A). Together with other factors it also stimulates ribosome binding and translation initiation⁶.

mTor, however, exists as two complexes: mTorC1 and mTorC2. Each complex is composed of different major regulators, differs in sensitivity to Rapamycin and has different cellular targets⁷. The major regulator of mTorC1, Raptor (regulatory-associated protein of mTOR), phosphorylates components of the translational machinery, namely ribosomal proteins (for instance RPS6 at Ser235/36) and the translational repressor 4E-BP1 (at Thr37/46/65/70). The major regulator of mTorC2, Rictor (Rapamycin-insensitive companion of mTOR), is Rapamycin-resistant and phosphorylates Akt (PKB) which in turn phosphorylates mTorC1. Preliminary investigations in bovine oocytes during IVM revealed different transient activities of mTorC1 and mTorC2 during IVM. In the GV-stage of oocytes the mTorC2 is active³; it is inactivated in the course of IVM. In contrast, mTorC1 shows the opposite behavior³. These results correspond with findings showing that 4E-BP1 phosphorylation is lower in the GV-stage, continuously increases during IVM, and is highest in the M II stage^{8,9}.

However, mTorC1 and C2 both respond to the active site inhibitor Torin2¹⁰ and might have other (yet unknown) targets. Candidates are meiotic spindle-forming or regulatory proteins, since mTor associates with meiotic spindles during chromatin segregation.

From a practical point of view, it should be noted that *in vitro* systems yield only 30-40 % transferable embryos in the bovine species¹¹. The causes for this could be suboptimal *in vitro* conditions and/or differences in the developmental competence of the starting oocytes which occur despite their selection from follicles of a defined size. However, detailed investigations of meiotic maturation on a molecular level can contribute to the optimization of IVM systems. Furthermore, oocytes might be selected according to their developmental competence, for instance by IVM systems under inhibitory conditions (see discussion). Hence, in the procedure presented here, we used two independent mTor inhibitors, Torin2 and Rapamycin, which resulted in different chromatin statuses and differential phosphorylation of 4E-BP1. Interestingly, approximately 20 % of the oocytes overcame the Torin2 block and might thus be candidates which possess a high developmental competence.

PROTOCOL:

All experiments were performed in accordance with the guidelines of the local ethics committee (Landesamt für Landwirtschaft, Lebensmittelsicherheit und Fischerei, Mecklenburg-Vorpommern, Germany). The ovaries were obtained from a commercial slaughterhouse. The remaining carcass was used for meat production.

1. Solutions to be prepared.

1.1) Prepare PBS for gaining oocytes by weighing Glucose (500 mg), Pyruvate (18 mg), Penicillin (10 mg), Streptomycin (20 mg), Heparin (5.6 mg) and BSA (150 mg) and add these substances to 500 mL PBS pH 7.4, supplemented with 1mM Ca²⁺/Mg²⁺. Store the solution until needed at 4°C (up to 2-3 days).

1.2) Prepare TCM as the maturation medium by weighing NaHCO₃ (220 mg), Gentamycin (5 mg), Pyruvate (2.2 mg) and TCM-199 Hepes modification (1510 mg) and add those substances to 100

mL ddH₂O. Mix the medium for 40 min on a magnetic stirrer. Adjust the pH-value to 7.4. Use a sterile filter to fill the solution into a small, sterile bottle. Store the solution until needed at 4°C (up to 2 weeks).

1.3) Prepare the Rapamycin working solution with a concentration 800 µM by dissolving 18.2 µg Rapamycin in 25 µL DMSO. Store the solution in aliquots of 5 µL at -20°C.

1.4) Prepare the 20 mM Torin2 stock solution by dissolving 10 mg Torin2 in 1.16 mL DMSO. Store aliquots of 10 µL at -20°C. Just before performing an experiment, take 3 µL of this stock solution and dilute it in 247 µL DMSO to prepare a working solution with a concentration of 240 µM.

1.5) Prepare 10 mL of the PBS as a washing buffer for immunohistochemistry. Supplement PBS with 0.5 % BSA and 0.05 % Triton-X-100.

1.6) Prepare 10 mL of the permeabilization buffer by weighing 0.46 g Hepes, 10.27 g sucrose, 0.29 g NaCl, 0.061 g MgCl₂ and 0.5 mL Triton-X-100. Fill up with ddH₂O and adjust to pH 7.4.

1.7) Prepare 10 mL of the blocking solution (BS) by diluting the commercial blocking solution 1:50 with ddH₂O.

1.8) Prepare the working solution for antibody incubation by diluting the BS solution with PBS, pH 7.4, 0.05 % Tween (1:1).

1.9) Fix and store the oocytes in 3 % paraformaldehyde, 2 % sucrose.

2. Source of oocytes and preparations before going to the slaughterhouse.

2.1) Prepare a NaCl-solution (0.9 %) by dissolving 9 g NaCl in 1 L ddH₂O. Warm this solution up to 37°C and fill it into a thermally insulated vessel.

2.2) Recover the ovaries at the slaughterhouse. Remove the ovaries with a pair of scissors from the carcasses of healthy cows immediately after the abdominal cavity is opened by a knife cut of about 40 cm in the ventral median line. Put the ovaries into the vessel with the NaCl-solution. Transport the ovaries back to the laboratory within 3 h after slaughter.

2.3) Puncturing of the follicles and gaining of the cumulus-oocyte complex's (COCs).

2.3.1) Use a 5 mL syringe to aspirate 1 mL warm PBS (37°C) first and then puncture the follicles (estimated follicle diameter: 4-8 mm). Remove the needle from the syringe and transfer the liquid in a plastic tube (50 mL) with a screwtop and keep it warm. Repeat the previous steps until all follicles sized 4-8 mm are aspirated.

2.3.2) Allow the aspirated liquid to stand for 10 min. The developing sediment contains approximately 400 COCs aspirated from 50 to 80 ovaries.

2.3.3) Use a Pasteur pipette to transfer sedimented COCs into screened Petri dishes with a

diameter of 90 mm. Add 5 mL PBS to each of the Petri dishes and store the dishes on a hotplate (37°C).

2.3.4) Take the COCs out of the Petri dishes with a pipette controller (use micropipettes with a volume of 20 µL) with the help of a stereomicroscope with 15x magnification and transfer them to smaller Petri dishes (diameter of 30 mm) filled with PBS.

2.4) Classification of the COCs¹²:

2.4.1) Use only COCs categorized as oocytes with a dark, homogenous cytoplasm and a compact (or only slightly expanded) cumulus oophorus that shows more than five layers of cumulus cells.

3. *In vitro* maturation and inhibitor treatment.

3.1) Preparing the maturation dishes.

3.1.1) Weigh 60 mg BSA and add it to 20 mL TCM and put it into the incubator for at least 1 h at 39°C, 5 % CO₂ and saturated humidity. Use a syringe with a sterile filter to distribute the TCM equally into two 30 mm Petri dishes.

3.1.2) Transfer 400 µL TCM from the two Petri dishes in each well of four 4-well dishes (these are the washing dishes), so that an equal amount of TCM remains in the Petri dishes.

3.1.3) Take 2760 µL of TCM from one Petri dish and add 40 µL of Rapamycin (800 µM) or Torin2 (240 µM)-working solution (these are the treatment media). Take 2760 µL of TCM from the other Petri dish and add 40 µL of DMSO (this is the control medium).

3.1.4) Add 350 µL of the treatment media and the control medium to each well of two 4-well dishes.

3.1.5) Transfer 25 COCs from the Petri dishes with PBS from point 2.3.5 / 2.4.1 after classification and put them into each well of the four 4-well washing-dishes.

3.1.6) Transfer the COCs from two 4-well-washing-dishes with a pipette using a volume of 50 µL to the two 4-well-dishes containing Rapamycin/Torin2 working solution, so that the total volume in each well is 400 µL and the final concentration is 3 µM for Torin2 and 10 µM for Rapamycin.

3.1.7) Do the same with the other washing dishes and the 4-well dishes containing DMSO for the control group. Put the dishes with the COCs into the incubator at 39°C, 5 % CO₂ and saturated humidity. Let the COCs mature there for 24 h.

4. Morphological inspection by Aceto-Orcein staining.

4.1) Fixation of the oocytes.

4.1.1) Prepare two 4-well-dishes with 400 µL PBS per well.

4.1.2) Transfer 100 oocytes of the Torin/Rapamycin group to well 1 of one of the 4-well dishes with PBS and 100 oocytes of the control group to the other well.

4.1.3) Denude the oocytes by repeated pipetting with 200 μ L pipette tips so that the cumulus cells are completely removed. Use the remaining 3 wells to wash the oocytes.

4.1.4) Prepare microscope slides as follows:

4.1.4.1) Apply two vertical parallel lines of silicone of medium viscosity with the help of a needle attached to a 2 mL-syringe spaced about 1.5 cm apart to each side of the microscope slide.

4.1.4.2) Use a pipette to transfer 10 oocytes in about 4 μ L PBS to the microscope slide. NOTE: The drop with the oocytes should be placed in the center between the two lines of silicone at one side of the microscope slide. Take a microscope cover glass (18x18 mm) and place it carefully onto the lines of silicone and the drop with the oocytes in between.

4.1.4.3) Press the cover glass lightly and carefully so that the oocytes do not burst. Put a drop of ethanol-glacial acetic acid (3:1) at one edge of the cover glass, so that the liquid may flow through the whole space in between cover glass and microscope slide and enclose the oocytes completely.

4.1.4.4) Put the microscope slides in a cuvette filled with 40 mL ethanol (absolute) glacial acetic acid (3:1). Ensure that the lower edges of the cover glasses are immersed in the liquid.

4.1.4.5) Seal the cuvette air tight with self-sealing lab film and store it at 4°C until staining. Keep the slides for no more than two weeks.

4.2 Staining of the oocytes.

4.2.1) Take the microscope slides out of the cuvette and dab them gently with a tissue. Apply 4 drops (approx. 40 μ L) of Aceto-Orcein-solution (2 %) to the upper edge of one cover glass so that the liquid is soaked under the cover glass.

4.2.2) Place a strip of filter paper at the lower edge of the cover glass to get the liquid completely soaked through the space between microscope slide and cover glass. Let the staining solution incubate for 10 min.

4.2.1) Apply drops of acetic acid (30 %) to the lower edge of one cover glass and use a strip of filter paper at the upper edge of the cover glass to get the liquid soaked through until the interstice is completely clear.

5. Evaluation.

5.1) Examine the stained slides under a phase-contrast microscope at 100-400x magnification. Classify the oocytes by reference to the chromatin configuration in metaphase II, anaphase II, telophase II, metaphase I, GVBD-stage, GV-stage and degenerate oocytes^{1,5}.

6. Western blotting was performed according to standard procedures¹³.

6.1) Subject 50 oocytes per lane to SDS-PAGE on 13 % (w/v) acrylamide gels with an acrylamide:

bisacrylamide ratio of 30:0.8. After transferring, block membranes with 5 % fat-free dry milk powder in TTBS for 1 hour at room temperature.

6.2) Dilute the primary antibodies as follows: 4E-BP1, 1:800; p4E-BP1-Thr37/46, 1:500; RPS6, 1:1000; pRPS6-Ser235/36, 1:1000. NOTE: In all cases, the HRP-labeled secondary antibody is four times more highly diluted than the primary. Perform ECL detection with a commercial kit.

7. Immunohistochemistry and Confocal Laser Scanning Microscopy (LSM)

7.1) Wash the fixed oocytes (1.9) once with PBS washing solution at room temperature. Incubate for 5 min in permeabilization solution at 0°C. Wash four times, 15 min in washing buffer. Incubate 2 h in blocking solution at room temperature.

7.2) Incubate the primary antibody (4EBP1, 1:100; p4E-BP1 Ser37/46, 1:200) overnight at 4°C without washing. Wash four times, 15 min in washing buffer. Incubate the secondary, fluorescence dye labeled antibody (1:200) for 5 h in the dark at room temperature. Wash four times, 15 min in washing buffer.

7.3) Stain the chromatin with SYBR green in the dark for 1 h. Wash four times, 15 min in washing buffer. Fix the oocytes in 2 % paraformaldehyde overnight at 4°C. Mount the oocytes in glycerin gelatin on microscopy slides.

7.4) Perform fluorescence analysis using a confocal laser scanning microscope. Track1: Laser: Argon 30mW (458/488/514nm) 488nm/12%; HFT/NFT: 488/545nm; Filter: BP 505-530nm Channel1 (Channel2 closed). Track2: Laser: HeNe 1mW (543) 543/60%; HFT/NFT: 543/545nm; Filter: LP 560-nm Channel2 (Channel1 closed). Pinhole: 1AU, gain constant, averaging: 2, Resolution 1024x1024. Stacks: 1 µm between slices.

REPRESENTATIVE RESULTS:

Source of oocytes, *in vitro* maturation and mTor inhibition

Figure 1 illustrates the collection of cumulus oocyte complexes (COCs) and the analysis of the chromatin configuration. Only healthy ovaries (Figure 1A) obtained from a local slaughterhouse were used as oocyte sources. COCs were aspirated from follicles sized 4-8 mm (Figure 1B). Only COCs with compact layers of cumulus cells (Figure 1C) were used for IVM and inhibitor studies. After IVM COCs were denuded and morphologically analyzed by aceto-orcein-staining. Before IVM (0 h, Figure 1D), oocytes were in the GV-stage. After 24 h IVM, oocytes reached the M II stage (Figure 1E) and after 10 h they were in M I stage (Figure 1F). Rapamycin treatment (10 µM) for 24 h, however, inhibited asymmetric cell division, i.e. polar body formation (Figure 1G). In contrast, application of Torin2 (3 µM) arrested oocytes in a stage comparable to M I (Figure 1H). However, in Torin2 treated samples, approximately 20 % of the oocytes overcame the mTor inhibition and reached M II stage³.

Analysis of the effects of Torin2 and Rapamycin on 4E-BP1 using Western blotting

Western blot analysis of the abundance and phosphorylation of 4E-BP1 and RPS6 are depicted in Figure 2. IVM in the control medium or treatment with Rapamycin (24R) or Torin2 (24T) did not

alter the 4E-BP1 and RPS6 abundances (Figure 2A-C left panels). However, phosphorylation and probably other posttranslational modifications of 4E-BP1 are accompanied by a pronounced band shift on SDS-gels. These findings are in accordance with previous observations^{8, 14}. Rapamycin-treated oocytes (24R; Figure 2A right panel) show the same level of phosphorylation of 4E-BP1 at Thr 37/46 as the untreated control (24; Figure 2A right panel). In contrast, Torin2 treatment clearly reduces the 4E-BP1 phosphorylation at these sites (Figure 2B, right panel, 24 vs 24T). RPS6 phosphorylation at Ser 235/36, however, is not reduced by Torin2 (Figure 2C right panel, 24 vs 24T).

Immunohistochemical analysis of Torin2 and Rapamycin effects on 4E-BP1

In general, SYBR green staining and immunohistochemical analysis of oocytes confirmed the results obtained by aceto-orcein-staining and Western blotting with regard to chromatin configuration, 4E-BP1 abundance (Figure 3A) and phosphorylation at Thr 37/46 (Figure 3B). For instance, the lowest phosphorylation of the protein is observed in the GV-stage (Figure 3B upper panel). A highly phosphorylated form is found in the M II stage and in Rapamycin-treated samples (Figure 3B second and third panel), whereas Torin2 treatment strongly reduced 4E-BP1 phosphorylation (Figure 3B lowest panel). Together, these approaches allow an overview of the distribution of 4E-BP1 in the oocyte. It is likely that some portions of phosphorylated 4E-BP1 are located at the metaphase I plate in Torin2-treated oocytes (Figure 3B, lowest panel).

FIGURE LEGENDS:

Figure 1: Source of oocytes, recovery of COCs and morphological evaluation. Only healthy ovaries were used as an oocyte source (A). COCs were aspirated from follicles of 4-8 mm in diameter with the help of a syringe (B). Only COCs with compact layers of cumulus cells were used for further investigations (C). After IVM, COCs were denuded by repeated pipetting. The chromatin status was inspected by morphological evaluation after aceto-orcein-staining. Control oocytes are in the GV-stage before IVM (D), more than 90 % have reached the M II-stage after 24 h (E) or the M I-stage after 10 h (F). Rapamycin treatment for 24 h prevents asymmetric division and polar body formation (G). Treatment with Torin2, however, arrests approximately 60 % of the oocytes in the M I-stage (H), whereas approximately 20 % enter the M II stage, also under inhibitory conditions. Arrows point to chromatin, scale bar 30 µM.

Figure 2: Analysis of the effects of the mTor inhibitors Rapamycin and Torin2 on the phosphorylation of specific target proteins by Western blotting. Depicted are Western blots revealing the abundance of 4E-BP1 (A) and (B) and RPS6 (C) obtained by Pan-antibodies (always left panel) and the corresponding blot analyzing the phosphorylation status of 4E-BP1 at Thr 37/46 and of RPS6 at Ser 235/36 (always right panels). The oocyte samples are analyzed before IVM (0), after 24 h (24) and after 24 h treatment with Rapamycin (24R) or Torin2 (24T), respectively.

Figure 3: Analysis of the effects of mTor inhibition on 4E-BP1 abundance and phosphorylation by confocal laser-scanning-microscopy (LSM). The results obtained by the Pan-antibody for 4E-BP1 (A) and the Thr 37/46 phosphorylated form of 4E-BP1 (B) are shown here. Controls (0 h and 24 h) and Rapamycin- (Rapa) or Torin2-treated samples are arranged as indicated. The left row

(red) shows the antibody staining, the middle row (green) shows the chromatin stained by SYBR green and the right row is the merged image. Scale bar: 50 μ m.

DISCUSSION:

In vitro maturation (IVM) of bovine oocytes is an important technique because it is an integral part of the in vitro production of embryos in specific breeding programs. However, a critical limitation is the fact that no method exists to assess the developmental competence of fully grown oocytes directly after follicular release. Furthermore, when the chromatin status of bovine oocytes is analyzed morphologically, more than 90 % have reached the M II stage after 24 h of IVM under standard conditions¹. However, transferable blastocysts can be produced from only 30-40 % of these oocytes¹¹. These results have led to the concept that the cytoplasmic maturation state may not correspond to the actual nuclear maturation state. Thus, IVM is also the subject of basic research, investigating the mechanisms of meiotic progression.

The asynchrony of nuclear and cytoplasmic maturation can be investigated by specific inhibition of mTor because the chromatin configuration and phosphorylation of cytoplasmic factors is differently influenced by Torin2 and Rapamycin. The application of specific, membrane-permeable inhibitors may help to facilitate the identification of distinct signaling cascades without the need for sophisticated devices like micro manipulators for the injection of macromolecules. On the other hand, the cytoplasmic maturation can be assessed by molecular and/or biochemical analysis, but in most cases the oocytes are lost for embryo production thereafter. Knockdown experiments are the gold standard to study critical control points in signal transduction pathways. However, in the early process of oocyte maturation large amounts of mRNA are stored in the oocyte to cover the translation during early embryonic development until the embryonic genome is activated (cattle: 8-cell stage). However, during the final maturation of the oocytes, de novo transcription is dramatically reduced. Therefore, knockdown experiments during this phase would not lead to relevant results. In addition, these knockdowns would result in unwanted effects in the later embryos. In contrast, the method shown here is able to provide significant results.

The most important modification of the standard technique for IVM in our experiments was the renunciation of the use of serum in the culture medium. Instead, we used BSA as a protein source. This resulted in lower rates of development to the metaphase II stage compared to the standard protocol³. However, the modification is necessary since serum components can interact with the inhibitors used. The modified IVM method can be regarded as a critical step in the methodology.

Several studies have been performed in an attempt to characterize cytoplasmic maturation specific kinase inhibitors^{1, 2, 16, 17}. However, when the function of the mTor axis was analyzed by specific inhibition, it was revealed that a portion of oocytes overcame the mTor block and reached the M II stage. For instance, the phosphatidylinositol analogue SH6 (which acts on Akt, PKB and therefore on mTorC1) leads to the M I arrest of approximately 60 % of the oocytes, whereas 30 % overcame the block and reached the M II stage¹⁶. A comparable result was achieved by applying the mTor inhibitor Torin²³. From these results, it can be concluded that

subclasses of oocytes exist which differ in their sensitivity to the inhibitor. The inhibitor-resistant oocytes may possess higher basal kinase activities in the GV stage¹⁸. Preliminary results from our pilot experiments suggest that these oocytes have high developmental competence with regard to blastocyst formation in vitro. Therefore, an IVM-system under Torin2 inhibitory conditions, followed by standard embryo production in vitro should enable the selection of more competent blastocysts and improve the yield of offspring after embryo transfer. However, this suggestion must be verified by additional experiments.

In the process of a possible troubleshooting, an exact definition of inhibitory but not toxic doses of the inhibitors is important. However, the inhibitors have to enter the relatively large oocyte via the zona pellucida. Therefore, when compared to somatic cells, much higher concentrations (10-100 fold) are required to obtain an effect. This increases the risk of side effects. For instance, we analyzed Torin2 effects by measuring the substrate phosphorylation of distinct kinases³ and found, in addition to the expected mTor and PKB inhibition, minor effects on CDKs. For this reason it is critical to determine the lowest concentration which produces clear and reproducible inhibitory effects.

In contrast to Torin2, were we could show a dose-response relationship for both the morphological effects and the BP1 phosphorylation³, the situation for Rapamycin is different. Other investigators showed a clear morphological effect and reduced 4E-BP1 phosphorylation in mouse oocytes treated with 100 nM Rapamycin⁵. It is generally known that oocytes from mice and cattle are different in size and particularly in the nature of the zona pellucida. Therefore the situation is not directly comparable. This could be the main reason that, in the application of 100 nM to 5 μ M Rapamycin, we did not observe any stable and reproducible effects in cattle either on morphological level or on the phosphorylation of any targets. However, from 10 μ M on we observed the described alterations in the chromatin configuration. Nevertheless, even this high concentration of the inhibitor did not result in any reduced phosphorylation of distinct mTor targets (4E-BP1; RPS6). This concentration (10 μ M) was used to show that mTor is required for asymmetric division in mouse oocytes¹⁵. This is the reason why we also used this concentration of rapamycin in our investigation. In conclusion it must be noted that the described effects of distinct inhibitors are species-specific. This represents a clear limitation of the technique. Nevertheless, the inhibition of mTor by small inhibitors might be a valuable tool to investigate nuclear as well as cytoplasmic maturation of oocytes.

Investigations using mouse oocytes revealed that, shortly after nuclear envelope breakdown, translational hotspots were found in the chromosomal area and in a region which was previously surrounded by the nucleus⁵. Moreover, actively translated mRNAs co-localize with meiotic spindles¹⁹. In other words, translational reprogramming of the oocyte occurs at the resumption of meiosis in a spatially and temporally regulated manner. Hence, one main challenge would be to characterize the mRNAs subjected to such a control. In this context, polysome profiling in combination with the inhibition studies as presented here can provide valuable results. Polysome profiling, where translationally active, ribosome-bound mRNAs are separated from translationally repressed, free mRNAs²⁰ is also possible with scarce samples like mammalian oocytes or early embryos²¹. Keeping in mind the different effect of the mTor inhibitors

Rapamycin and Torin2 on the chromatin status, it is likely that the application of these substances also leads to a different pattern of actively translated mRNA. Together with, for instance, RNA-sequence approaches²², such comprehensive investigations can provide information about proteins which attend nuclear envelope breakdown, spindle regulation, M I to M II transition, asymmetric division and polar body formation.

In conclusion, basic inhibition studies as presented here can be valuable in practical terms for selecting oocytes according to their developmental competence and can provide tools for detailed basic research on a molecular level.

ACKNOWLEDGMENTS:

Manuela Kreißelmeier and Sophia Mayer were scholarship holders of the Dr. Dr. Karl-Eibl-Stiftung. We wish to thank Gesine Krüger and Petra Reckling for excellent technical assistance.

DISCLOSURES:


The authors have nothing to disclose.

REFERENCES:

1. Kubelka, M., Motlik, J., Schultz, R.M., Pavlok, A. Butyrolactone I reversibly inhibits meiotic maturation of bovine oocytes, without influencing chromosome condensation activity. *Biol Reprod* **62**, 292–302, doi: 10.1095/biolreprod62.2.292, (2000).
2. Kalous, J., Solc, P., Baran, V., Kubelka, M., Schultz, R.M., Motlik, J. PKB/AKT is involved in resumption of meiosis in mouse oocytes. *Biology of the Cell* **98**, 111-123, doi: 10.1042/BC20050020, (2006).
3. Mayer, S., Wrenzycki, C., Tomek, W. Inactivation of mTor arrests bovine oocytes in the metaphase-I stage, despite reversible inhibition of 4E-BP1 phosphorylation. *Mol Reprod Dev* **81** (4), 363-75, doi: 10.1002/mrd.22305, (2014).
4. Dowling, R.J., *et al.* mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. *Science* **328**, 1172-1176, doi: 10.1126/science.1187532, (2010).
5. Susor, A., *et al.* Temporal and spatial regulation of translation in the mammalian oocyte via the mTOR-eIF4F pathway. *Nat Commun* **28** (6), 6078, doi: 10.1038/ncomms7078, (2015).
6. Tomek, W., Wollenhaupt, K. The “closed loop model” in controlling mRNA translation during development. *Anim Reprod Sci* **134**, 2-8, doi: 10.1016/j.anireprosci.2012.08.005, (2012).
7. Ballou, L.M., Lin, R.Z. Rapamycin and mTOR kinase inhibitors. *J Chem Biol* **1**, 27-36, doi: 10.1007/s12154-008-0003-5, (2008).
8. Ellederova, Z., Kovarova, H., Melo-Sterza, F., Livingstone, M., Tomek, W. and Kubelka, M. Suppression of translation during in vitro maturation of pig oocytes despite enhanced formation of cap-binding protein complex eIF4F and 4E-BP1 hyperphosphorylation. *Mol Reprod Dev* **73**, 68–76, doi: 10.1002/mrd.20368, (2006).
9. Siemer, C., *et al.* Analysis of mRNA associated factors during bovine oocyte maturation and early embryonic development. *Mol Reprod Dev* **76**, 1208-1219, doi: 10.1002/mrd.21096, (2009).
10. Liu, Q., *et al.* Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. *Cancer Res* **73**, 2574-86, doi: 10.1158/0008-5472.CAN-12-1702, (2013).

11. Wrenzycki, C., Stinshoff, H. Maturation Environment and Impact on Subsequent Developmental Competence of Bovine Oocytes. *Reprod Dom Anim* **48** (Suppl. 1), 38–43, doi: 10.1111/rda.12204, (2013).
12. Leibfried, L., First, N.L. Characterization of Bovine Follicular Oocytes and Their Ability to Mature In Vitro. *J. Anim Sci* **48**, 76-86, doi:10.2134/jas1979.48176x, (1979)
13. Eslami, A., Lujan, J. Western Blotting: Sample Preparation to Detection. *J Vis Exp* (44), e2359, doi:10.3791/2359 (2010).
14. Wollenhaupt, K., *et al.* Natural occurrence and physiological role of a truncated eIF4E in the porcine endometrium during implantation. *Biochem J* **432**, 353-363. doi:10.1042/BJ20100801 (2010).
15. Lee, S.E., Sun, S.C., Choi, H.Y., Uhm, S.J. and Kim, N.H. mTOR is required for asymmetric division through small GTPases in mouse oocytes. *Mol Reprod Dev* **79**, 356–366, 2012. doi: 10.1002/mrd.22035
16. Tomek, W., Smiljakovic, T. Activation of Akt (protein kinase B) stimulates metaphase I to metaphase II transition in bovine oocytes. *Reproduction* **130**, 423-430, doi: 10.1530/rep.1.00754, (2005).
17. Tomek, W., *et al.* Regulation of translation during in vitro maturation of bovine oocytes: the role of MAP kinase, eIF4E (cap binding protein) phosphorylation, and eIF4E-BP1. *Biol Reprod* **66**, 1274-1282, doi: 10.1095/biolreprod66.5.1274, (2002).
18. Torner, H., *et al.* Molecular and subcellular characterization of oocytes screened for their developmental competence based on glucose-6-phosphate dehydrogenase activity. *Reproduction* **135**, 197-212, doi: 10.1530/REP-07-0348, (2008).
19. Romasko EJ, Amarnath D, Midic U, Latham KE. 2013. Association of Maternal mRNA and Phosphorylated EIF4EBP1 Variants with the Spindle in Mouse Oocytes: Localized Translational Control Supporting Female Meiosis in Mammals. *Genetics* **195** (2), 349-58, doi: 10.1534/genetics.113.154005, (2013).
20. Morita, M., Alain, T., Topisirovic, I. and Sonenberg, N. Polysome Profiling Analysis. *Bio-protocol* **3** (14), e833. SOURCE: <http://www.bio-protocol.org/e833>. (2013).
21. Scantland, S., Grenon, J.P., Desrochers, M.H., Sirard, M.A., Khandjian, E.W., Robert, C. Method to isolate polyribosomal mRNA from scarce samples such as mammalian oocytes and early embryos. *BMC Dev Biol* **11** (8), doi: 10.1186/1471-213X-11-8, (2011).
22. Reyes, J.M., Chitwood, J.L., Ross, P.J. RNA-Seq profiling of single bovine oocyte transcript abundance and its modulation by cytoplasmic polyadenylation. *Mol Reprod Dev* **82**, 103–114, 2015. doi: 10.1002/mrd.22445 (2015).

Figure 1
[Click here to download Figure: Grafik1.JPG](#)







Figure 3
[Click here to download Figure: submission3.jpg](#)



Name of Reagent/ Equipment	Company	Catalog Number	Comments/Description
PBS Dulbecco wCa2+ wMg2+	Biochrom AG	L1815	For gaining of the COC and denudation
D-(+)-Glucose	Sigma	G5400-250G	Supplement to PBS Dulbecco
Sodium pyruvate	Sigma	P3662-25G	Supplement to PBS Dulbecco
Penicillin G sodium salt	Sigma	P3032-25 MU	Supplement to PBS Dulbecco
Streptomycin sulfate salt	Sigma	S1277-50G	Supplement to PBS Dulbecco
Heparin sodium salt	Sigma	H3149-25 KU	Supplement to PBS Dulbecco
Bovine serum albumin	Sigma	A9647-10G	Supplement to PBS Dulbecco
Sodium bicarbonate (NaHCO3)	Sigma	S4019-500G	Supplement to PBS Dulbecco
Gentamicin sulfate salt	Sigma	G3632-250MG	Component of TCM medium
TCM-199 Hepes Modification	Sigma	M2520-1L	Component of TCM medium
Sodium chloride (NaCl)	Sigma	S5886-500G	Component of 0.9% NaCl solution
	Cell Signaling		
Rapamycin	Technology (CST)	9904 S	m-Tor-inhibitor
Dimethyl sulfoxide (DMSO)	Serva	39757.01	Used as solubilizer for Rapamycin and Torin 2
Torin 2	R&D Systems	4248/10	m-Tor-inhibitor
Phosphat Buffered Saline Tablets (PBS)	Sigma	P-4417	for PBS-präparation
Tween 20	Serva	39796.01	permeabilization buffer
Roti-Immuno-Block	Roth	T144.1	Blockingsolution+Lsg.für AK
Triton X100	Serva	37240	permeabilization buffer
Hepes	Serva	25245	permeabilization buffer
Albumin Fraktion V(biotinfrei)	Roth	0163.3	permeabilization buffer
D(+)-Saccharose	Roth	4621.1	permeabilization buffer
Nacl	Roth	3957.1	permeabilization buffer
MgCl2x6 H2O	Sigma	M2393	permeabilization buffer
Paraformaldehyde	Sigma	P-6148	Fixation
Kaisers Glyceringelatine	Merck	109,242	cover oocytes
Alex-Fluor 546F(ab)2 fragment goat anti rabbit IgG(H+L)	MOBITEC	A11071	secondary antibody fluorecent labeled
SYBR Green nucleic acid gel stain	Invitrogen	S7563	DNA staining

4E-BP1	CST		9452	primary antibody
p4E-BP1 Thr37/46	CST		2855	primary antibody
anti rabbit IgG-HRP	CST		7074	secondary antibody HRP labelled
ECL prime	GE healthcare	RPN2232		WB detection
Fluid filter Infufl 0,2µm 5,7 cm2	Fresenius Kabi		2909702	Used for sterile filtration
Pipette pipetman P10 0,1-10µl	Gilson			Used for transferring denudated oocytes and embryo
Pipette Reference 10-100µl	Eppendorf	4920000059		Used for transferring COC and volumina of 10-100µl a
Pipette Reference 100-1000µl	Eppendorf	4920000083		Used for transferring volumina of 100-1000µl
Micro-classic pipette controller	Brand		25900	Used for transferring COC
Micropipettes intraMark 20µl	Brand		708718	Used for transferring COC
Safe-lock tubes 0,5 ml	Eppendorf	0030 121.570		Used to store volumina up to 0,5 ml
Polypropylene centrifuge tube with conical base 50 ml, 30,0/115mm	Greiner		210261	Used for the aspirated fluid to sediment
Pasteur pipette 7 ml	VWR	612-1681		Used for transferring the sediment to screened Petri c
Germ count dish with vents 90/16 mm	Greiner		633175	Used for searching the COC
Petri dish with vents 35/10 mm	Greiner		627102	Used for medium preparation, washing the COC
Petri dish with vents 60/15 mm	Greiner		628102	Used for medium preparation
Multidish 4 wells	Thermo Scientific		176740	Used for washing the COC, for COC maturation, embri
Tissue culture dish 35/10 mm, 4 compartments	Greiner		627170	Used for washing the COC
Microscope slides 76x26x1mm	Thermo Scientific	AB00000112E		For fast morphological inspection by Aceto-Orcein-sta
Microscope cover glasses, 18x18 mm	VWR	ECN 631-1567		For fast morphological inspection by Aceto-Orcein-sta
Needle 18G x 1 1/2" 1,2 x 40 mm	BD Microlance	REF 304622		For medium preparation
Incubator inc108med with CO2 control	Memmert		84198998	Used for in vitro maturation
Universal oven model UNB 200	Memmert		84193990	Used for medium preparation
Control unit HAT 400 W1, 72VA 470 x 263 mm	Minitube	12055/0400		Used for keeping the cells warm in the course of treat

confocal laser scanning
microscope, phase contrast
microscope

Zeiss

Model: LSM 5
PASCAL Axiovert
200 M

Morphological and immuno-histochemical analysis of

s and volumina of 0,1-10μl
nd for denudation

dishes

yo culture and for denudation of the oocytes

ining

ining

:ment

oocytes



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Manuscript #:

JOVE 53222

Title of Article:

Inactivation of mTOR: A tool to investigate...

Author(s):

Kraußharmer M, Mayer S, Wenzel C, Pohlmann R, Tomkowiak W

Item 1 (check one box): The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via: ☒ Standard Access ☐ Open Access

Item 2 (check one box):



The Author is NOT a United States government employee.



The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.



The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: "**Agreement**" means this Article and Video License Agreement; "**Article**" means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; "**Author**" means the author who is a signatory to this Agreement; "**Collective Work**" means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; "**CRC License**" means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; "**Derivative Work**" means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; "**Institution**" means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; "**JoVE**" means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; "**Materials**" means the Article and / or the Video; "**Parties**" means the Author and JoVE; "**Video**" means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties,

incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the

ARTICLE AND VIDEO LICENSE AGREEMENT

Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. Grant of Rights in Video – Standard Access. This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. Grant of Rights in Video – Open Access. This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government

employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. Likeness, Privacy, Personality. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. JoVE Discretion. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each

ARTICLE AND VIDEO LICENSE AGREEMENT

such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or

decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

CORRESPONDING AUTHOR:

Name: Dr. Wolfgang Tomet
Department: Reproductive Biology
Institution: Leibniz-Institute for Farm Animal Biology
Article Title: Inactivation of mTOR: A tool to investigate...
Signature: [Signature] Date: 05/11/2015

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email submissions@jove.com or call +1.617.945.9051

Editorial comments:

1. Thank you so much for submitting your revised manuscript. All of your previous revisions have been incorporated into the most recent version of the manuscript. Please download this version of the Microsoft word document from the "file inventory" to use for any subsequent changes (File name: 53689).

→ done

2. Some of the editorial comments haven't been addressed. For example, please see the following.

→ done

3. Short abstract – Please fix the second sentence, which is a run on sentence.

→ done

4. In step 2.4.1, please clarify “almost not less than five.”

→ done

5. Please check for grammar in step 4.1.4.4.

→ done by native speaker (language service)

6. In step 6.2, the statement should read “After transferring, block...”. Please ensure that all the steps of the protocol section are written in imperative tense. This is very important for scripting and filming.

→ done

7. In step 2.3.1 “estimated in size..mm” should be mentioned in parenthesis. This is very confusing with the current grammar. Are you trying to puncture holes of 4-8 mm size?

→ done

8. The discussion part should have the following sections. This is still not clear.

a. Critical steps within the protocol.

b. Modifications and troubleshooting.

c. Limitations of the technique.

d. Significance of the technique with respect to existing/alternative methods.

e. Future applications or directions after mastering this technique.

→ done (The Discussion was reorganized and supplemented accordingly.)

9. Please note that while many of the editorial comments have been addressed, there are still some concerns regarding the language and grammar in your article. Our editors will not copy-edit your submission to correct these issues. Additionally, your article will not be able to proceed to production until these errors are corrected. Please thoroughly review the language and grammar of your article text prior to resubmission, preferably by a Native-American speaker or professional editing services. Failure to address these concerns will prohibit us from being able to proceed with review of your article.